Physical Activity Intervention for MPS

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBrunel University

About this trial

Currently, treatments for mucopolysaccharidoses (MPS) are pharmacological and predominantly focus on the physical symptoms of the disease. In the general population and individuals with disabilities, increasing physical activity levels and reducing sedentary time can be an effective, non-pharmacological treatment to improve mental health and quality of life. Such interventions have not yet been developed or evaluated in people with MPS.

The aim of this study is to co-design a physical activity and sedentary behaviour intervention tailored to the needs of adults with MPS. The study will seek to gain the expertise of adults with MPS, specialist stakeholders (physicians and clinical nurse specialists) and lay specialist stakeholders (family and friends of adults with MPS and members of staff and volunteers at the Society for Mucopolysaccharide Diseases). A range of views and experiences of physical activity and sedentary behaviour will be explored via focus groups (with individuals with MPS and lay specialist stakeholders) and semi-structured interviews (with specialist stakeholders). The information gathered from the focus groups and interviews will then be utilised to inform participatory workshops (with individuals with MPS) to test intervention concepts. Data from these activities will inform the design of a future intervention.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Diagnosed with any type of Mucopolysaccharidosis.

Aged ≥ 18 years old.

Lives in the United Kingdom.

Deemed safe to participate by a clinician (for participatory workshops).

Disqualifiers

Incapacity to provide informed consent.

A level of intellectual disability that would prevent the individual from making a meaningful contribution to the focus groups or workshops.

Unable to communicate in English to a sufficient level to permit engagement in the study.

Severe joint pain.

Trial population

Adults with Mucopolysaccharidosis, lay specialist stakeholders and specialist stakeholders who meet the eligibility criteria.

Trial design

Design model

Other

Time perspective

Cross-sectional

Treatments tested in this trial

  • Interviews/focus groups/participatory workshops

    Other intervention

    Qualitative study (no intervention delivered)

Treatment groups

50 Participants
are divided into 3 treatment groups
Group A: Adults with Mucopolysaccharidosis1 intervention
Group B: Lay specialist stakeholders1 intervention
Group C: Specialist stakeholders1 intervention

Trial outcomes

Primary outcomes

1

Focus groups (adults with Mucopolysaccharidosis)

Themes describing adults with Mucopolysaccharidosis' views and experiences of physical activity and sedentary behaviour- Emergence of themes describing participants' views and experiences from analysis of focus groups (using the Framework Method).

Time frame
7 months
2

Focus groups (lay specialist stakeholders)

Themes describing lay specialist stakeholders' views and experiences of physical activity and sedentary behaviour- Emergence of themes describing participants' views and experiences from analysis of focus groups (using the Framework Method).

Time frame
7 months
3

Semi-structured interviews (specialist stakeholders)

Themes describing specialist stakeholders' views and experiences of physical activity and sedentary behaviour- Emergence of themes describing participants' views and experiences from analysis of interviews (using the Framework Method).

Time frame
7 months
4

Participatory workshops (adults with Mucopolysaccharidosis)

Themes describing adults with Mucopolysaccharidosis' views and experiences of initial intervention concepts- Emergence of themes describing participants' views and experiences from analysis of participatory workshops (using the Framework Method).

Time frame
7 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Brunel University

Lead sponsor

University College London Hospitals

Collaborator

Northern Care Alliance NHS Foundation Trust

Collaborator

Royal Free Hospital NHS Foundation Trust

Collaborator